Galapagos NV (GLPG.BR) Release: First Clinical Centers Opened For Phase 2 Crohn's Study With GLPG0634
1/30/2014 8:59:40 AM
MECHELEN, Belgium, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today that the first clinical centers have been opened for enrolment in the Phase 2 clinical study in Crohn's disease with GLPG0634, a selective JAK1 inhibitor. The Phase 2 study will evaluate the efficacy and safety of GLPG0634 during 20 weeks of treatment in 180 patients with active Crohn's disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by